Medtronic Diabetes
Medtronic Diabetes (Medtronic MiniMed, Inc.) designs and sells automated insulin delivery systems and continuous glucose monitors—including MiniMed 780G, Flex, Go, and Simplera sensors—for Type 1 and insulin-requiring Type 2 diabetes patients, generating approximately $2.5–2.8 billion in annual revenue.
- Company typePrivate
- Founded2001
- HeadquartersNorthridge, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Medtronic Diabetes does
Medtronic Diabetes, operating as Medtronic MiniMed, Inc., is a medical device company specializing in automated insulin delivery (AID) systems and continuous glucose monitoring (CGM) for diabetes management. The company is the only manufacturer producing both insulin-delivery pumps and CGMs, enabling fully integrated closed-loop systems through its proprietary SmartGuard technology, which automatically adjusts insulin delivery every 5 minutes based on real-time CGM readings and can predict and prevent hypoglycemic events. Its product portfolio includes the flagship MiniMed 780G system (advanced AID pump with SmartGuard), MiniMed Flex (compact AID pump), MiniMed Go (smart MDI system integrating InPen smart insulin pen with Abbott CGM sensors), and CGM sensors including Simplera Sync, Guardian 4, and Abbott's Instinct sensor. The company also deploys the DreaMed AI-powered algorithm for optimized insulin delivery calculations.
The business generates revenue through hardware sales (insulin pumps, CGM sensors) and recurring subscription-like auto-supply programs (infusion sets, replacement sensors). Medtronic's Diabetes division generates approximately $2.5–2.8 billion in annual revenue, ranking third globally among diabetes technology companies behind Abbott ($5.8B) and Dexcom ($3.6B). The company distributes through direct-to-consumer e-commerce (diabetes.shop), healthcare provider prescriptions, Medicare/insurance coverage pathways, and phone support (1-800-MINIMED), handling insurance verification internally.
Medtronic Diabetes operates as a division of Medtronic plc (NYSE: MDT), with the diabetes business headquartered in Northridge, California. In May 2025, Medtronic announced the spin-off of the diabetes business into a standalone direct-to-consumer company valued at $2.8 billion. The company serves primarily Type 1 diabetes patients, with recent FDA clearances expanding into insulin-requiring Type 2 diabetes patients and pediatric populations (ages 2+). Recent strategic moves include a partnership with Abbott for exclusive CGM integration, multiple FDA clearances, and Medicare coverage expansion for the MiniMed 780G system.
Medtronic Diabetes firmographics
Firmographics- Name
- Medtronic Diabetes
- Legal name
- Medtronic MiniMed, Inc.
- Website
- https://medtronicdiabetes.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medtronic Diabetes (Medtronic MiniMed, Inc.) designs and sells automated insulin delivery systems and continuous glucose monitors—including MiniMed 780G, Flex, Go, and Simplera sensors—for Type 1 and insulin-requiring Type 2 diabetes patients, generating approximately $2.5–2.8 billion in annual revenue.
- Ownership category
- akta.pro rank
Medtronic Diabetes industry classification
Industry- Product category
- Insulin Pumps and Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
- akta.pro secondary industries
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC), Insulin Pumps (Tubed) (HLAHAHAB), Smart Insulin Pens & Connected Pen Caps (HLAHAHAD), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where Medtronic Diabetes is headquartered
LocationHeadquarters
- HQ city
- Northridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Medtronic Diabetes business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel, Infrastructure
Revenue model
- Insulin Delivery Devices: Sale of insulin pumps including MiniMed 780G, MiniMed Flex, and related accessories. Medtronic's Diabetes division generates approximately $2.5B in annual revenue, making it the third-largest diabetes technology company.
- CGM Sensors and Accessories: Continuous glucose monitoring sensors including Simplera Sync, Guardian 4, and compatibility with Abbott's Instinct sensor. Ongoing consumable revenue from sensor replacements.
- Infusion Sets and Supplies: Ongoing supplies including infusion sets (7-day wear), sensors, and other diabetes management consumables delivered through subscription-like auto-supply programs.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Medtronic Diabetes product offering
Product offeringCore offering
Medtronic Diabetes (operating as MiniMed) designs, manufactures, and sells automated insulin delivery systems, continuous glucose monitoring sensors, and smart insulin pens for people with Type 1 and insulin-requiring Type 2 diabetes. Its flagship products include the MiniMed 780G and MiniMed Flex insulin pumps featuring SmartGuard technology, alongside the MiniMed Go smart MDI system integrating Abbott CGM sensors with the InPen smart insulin pen.
Product overview
Medtronic Diabetes (operating as MiniMed) offers a comprehensive insulin delivery and glucose monitoring ecosystem. The portfolio centers on automated insulin delivery (AID) systems including the MiniMed 780G and MiniMed Flex insulin pumps, both featuring SmartGuard technology that automatically adjusts insulin delivery based on real-time CGM data. For multiple daily injection (MDI) users, MiniMed Go integrates Abbott's CGM sensors with the InPen smart insulin pen via a mobile app. The company supports multiple CGM sensors (Simplera Sync, Guardian 4, and Abbott's Instinct) across its platforms, providing patients and healthcare providers flexibility in diabetes management. Medtronic's diabetes business generates approximately $2.8 billion in annual revenue and is structured as a standalone direct-to-consumer company following a spinoff from Medtronic plc.
Differentiator
Problem solved
Functional benefit
Brands
- MiniMed 780G: Advanced automated insulin delivery system with SmartGuard technology that automatically adjusts insulin delivery every 5 minutes based on CGM readings.
- MiniMed Go
- MiniMed Flex
- InPen
- Simplera Sync
- Guardian 4
Products and services
- MiniMed 780G System Advanced automated insulin delivery system that automatically corrects sugar levels every 5 minutes based on real-time CGM readings to optimize Time in Range. Features SmartGuard technology, a 15-day sensor, and a 7-day infusion set. FDA-cleared for Type 1 diabetes patients ages 7 and older and Type 2 diabetes patients ages 18 and older requiring insulin.
- MiniMed Flex System
Quantifiable outcome
- Time in Range optimization through automated insulin adjustments every 5 minutes
- +1 more outcomes
Companies that use Medtronic Diabetes
Customer profileSegments3 records
Ideal customer profiles3 records
Medtronic Diabetes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature7 records
Medtronic Diabetes partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AbbottcoreMedtronic and Abbott announced a strategic partnership where Abbott will develop a continuous glucose monitor exclusively compatible with Medtronic's insulin pump devices. The deal addresses Medtronic's longstanding weakness in CGM technology, with analysts projecting it could boost Medtronic's diabetes business revenues long-term by providing patients with more integrated options for diabetes management. Medtronic also submitted an FDA clearance application for pairing its pumps with Abbott FreeStyle Libre CGM technology. The MiniMed Go system is already cleared for use with Abbott's Instinct CGM sensor.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Medtronic Diabetes competitors and assessment
Company assessmentBroad incumbents
- LifeScan: LifeScan (OneTouch) is a blood glucose monitoring company now owned by Platinum Equity. Adjacent peer in the diabetes monitoring space; while it focuses on BGM rather than CGM and pumps, it serves the same diabetes patient population with overlapping chronic-condition management offerings.
- Roche Diabetes Care: Roche's Diabetes Care division produces Accu-Chek insulin pumps, BGMs, and digital diabetes management tools under a broader diagnostics conglomerate. Overlaps with Medtronic in insulin pumps and glucose monitoring, but with a smaller share and broader healthcare portfolio focus.
- Novo Nordisk: Novo Nordisk is the global leader in insulin manufacturing and increasingly in GLP-1 therapies (Ozempic, Wegovy). Indirect peer/partner given its insulin pen portfolio competes with Medtronic's InPen smart pen integrations, and its GLP-1 drugs could reduce future insulin pump demand.
Direct peers
- Insulet Corporation: Insulet's Omnipod is a tubeless, wearable patch insulin pump that has been gaining share against Medtronic's tubed MiniMed systems, including via AID integration with Dexcom CGMs. Direct pump-market competitor targeting the same Type 1 patient population.
- Dexcom: Dexcom is a leading CGM manufacturer with $3.6B in revenue, the closest direct competitor to Medtronic in diabetes technology. Dexcom partners with pump makers including Insulet (Omnipod) and Tandem, competing with Medtronic's integrated pump + CGM stack and driving the need for Medtronic's Abbott partnership.
- Tandem Diabetes Care: Tandem manufactures the t:slim X2 insulin pump with Control-IQ hybrid closed-loop algorithm integrating Dexcom CGMs. A direct competitor to Medtronic's MiniMed 780G in the AID segment, particularly popular with Type 1 patients seeking smaller form factors.
- Abbott Diabetes Care: Abbott's Diabetes Care division ($5.8B revenue, the largest in diabetes tech) makes FreeStyle Libre CGMs and is Medtronic's exclusive CGM partner for the Instinct sensor. Direct overlap with Medtronic's CGM line and competing for the same insulin-requiring patient population.
Regional players
- Ypsomed: Ypsomed manufactures the mylife YpsoPump insulin pump and offers an AID system (mylife Loop) integrated with Dexcom CGMs, primarily serving European markets. Comparable to Medtronic's pump business in functionality and target patient base, but with limited US presence.
Emerging players
- Bigfoot Biomedical: Bigfoot Unity was a connected insulin pen system with CGM integration, directly comparable to Medtronic's MiniMed Go / InPen offering. An emerging player focused on smart MDI users rather than pump users, addressing an adjacent segment with overlapping technology.
- Beta Bionics: Beta Bionics makes the iLet bionic pancreas, an automated insulin delivery system that requires no carb counting. Emerging competitor in the AID segment addressing similar Type 1 diabetes patients as Medtronic's MiniMed 780G with a differentiated algorithmic approach.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Medtronic Diabetes social profiles
Digital presenceMedtronic Diabetes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medtronic Diabetes leadership team
Management profileNumber of profiles
Profiles1 record
Medtronic Diabetes funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medtronic Diabetes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medtronic Diabetes
What does Medtronic Diabetes do?
Medtronic Diabetes (operating as MiniMed) designs, manufactures, and sells automated insulin delivery systems, continuous glucose monitoring sensors, and smart insulin pens for people with Type 1 and insulin-requiring Type 2 diabetes. Its flagship products include the MiniMed 780G and MiniMed Flex insulin pumps featuring SmartGuard technology, alongside the MiniMed Go smart MDI system integrating Abbott CGM sensors with the InPen smart insulin pen.
Is Medtronic Diabetes a public or private company?
Medtronic Diabetes is a private company. It is classified as public and is currently operating.
When was Medtronic Diabetes founded?
Medtronic Diabetes was founded in 2001. It employs 11 to 50 people.
Where is Medtronic Diabetes based?
Medtronic Diabetes is headquartered in Northridge, United States, in the North America region.
How does Medtronic Diabetes make money?
Three revenue lines are on record. Insulin Delivery Devices are the primary driver. The others are CGM Sensors and Accessories and infusion Sets and Supplies.
Who are Medtronic Diabetes's main competitors?
Broad incumbents on record are LifeScan, Roche Diabetes Care and Novo Nordisk. Direct peers are Insulet Corporation, Dexcom, Tandem Diabetes Care and Abbott Diabetes Care. Ypsomed is listed as a regional player. Emerging players are Bigfoot Biomedical and Beta Bionics.
Does Medtronic Diabetes have an API?
No public API is recorded for Medtronic Diabetes.
What industry is Medtronic Diabetes in?
Medtronic Diabetes's product category is Insulin Pumps and Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAC, Patch Pumps & Wearable Insulin Delivery. Its NAICS code is 334510 and its SIC code is 3845.